Long-term safety follow-up for CTX0E03 after PISCES III
Part of Brain & nervous system, Heart & circulation clinical trials.
This study checks how safe CTX0E03 is over the long term in people who already received it in a previous PISCES III trial. It may help confirm long-term safety information for future patients, and you may contribute valuable follow-up data.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the PISCES III study.
- You received CTX0E03 during the active (treatment) part of PISCES III.
- You signed (or can sign) written informed consent for this follow-up study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called LWP779 in healthy adults to see if it is safe and how the body processes it. It helps determine the right dose for future studies.
This study monitors the safety and effectiveness of already-approved devices used to remove blood clots from the brain during an ischemic stroke. It aims to gather more information about how these devices work in real-world patients to help improve stroke care.
This study looks for biological and imaging markers that may predict heart/vascular outcomes after an ischemic stroke. You may join if you are eligible for standard stroke treatment and can complete planned follow-up and MRI scans.
This study is a long-term follow-up for people with epilepsy who already completed a previous trial of the drug CB03-154. It checks if the drug remains safe and effective over more time.
This trial tests whether XY03-EA tablets can help people recover after an acute ischemic stroke. Participants must have had a stroke within the last 48 hours and have moderate to severe symptoms but not be in a coma.
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.